Genus/£GNS
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About Genus
Genus PLC, trading under the ticker GNS on the London Stock Exchange, specializes in animal genetics and biotechnology. The company, founded in 1994 and headquartered in Basingstoke, United Kingdom, operates across multiple countries offering genetically superior pig and cattle breeding stock along with state-of-the-art in vitro fertilization products. Genus PLC aims to empower customers in the livestock sector to enhance the efficiency and profitability of their operations by providing innovative genetic solutions and services.
Ticker
£GNS
Sector
Primary listing
LSE
Employees
3,190
Headquarters
Website
Genus Metrics
BasicAdvanced
£1.8B
92.56
£0.29
0.62
£0.32
1.20%
Price and volume
Market cap
£1.8B
Beta
0.62
52-week high
£32.29
52-week low
£14.24
Average daily volume
170K
Dividend rate
£0.32
Financial strength
Current ratio
1.938
Quick ratio
1.272
Long term debt to equity
52.458
Total debt to equity
55.861
Dividend payout ratio (TTM)
109.33%
Interest coverage (TTM)
3.10%
Profitability
EBITDA (TTM)
91.5
Gross margin (TTM)
40.19%
Net profit margin (TTM)
2.87%
Operating margin (TTM)
10.15%
Effective tax rate (TTM)
32.28%
Revenue per employee (TTM)
£210,000
Management effectiveness
Return on assets (TTM)
4.52%
Return on equity (TTM)
3.90%
Valuation
Price to earnings (TTM)
92.561
Price to revenue (TTM)
2.621
Price to book
3.73
Price to tangible book (TTM)
5.58
Price to free cash flow (TTM)
36.278
Free cash flow yield (TTM)
2.76%
Free cash flow per share (TTM)
0.737
Dividend yield (TTM)
1.20%
Growth
Revenue change (TTM)
0.60%
Earnings per share change (TTM)
142.86%
3-year revenue growth (CAGR)
4.27%
10-year revenue growth (CAGR)
5.38%
3-year earnings per share growth (CAGR)
-22.55%
10-year earnings per share growth (CAGR)
-7.77%
10-year dividend per share growth (CAGR)
5.08%
What the Analysts think about Genus
Analyst ratings (Buy, Hold, Sell) for Genus stock.
Bulls say / Bears say
Genus has achieved U.S. FDA approval for its PRRS-Resistant Pig (PRP) gene edit, marking a crucial step forward in commercializing its leading gene-editing program.
The PRP initiative targets the U.S. pork sector, which suffers annual losses of up to $1.2 billion due to PRRS; this could drive significant growth for Genus from fiscal year 2027 onwards.
Genus’s solid market position in Brazil should help offset the impact of retaliatory tariffs in the U.S., supporting ongoing demand for its gene-edited pigs internationally.
PRP will not meaningfully contribute to Genus’s income until fiscal year 2027, resulting in a prolonged period without revenue from this initiative and increasing the company’s reliance on its current core breeding business.
Retaliatory export tariffs on U.S. pork could weaken international demand for PRP gene-edited pigs, especially in Japan, Canada, and Mexico, which may limit sales growth.
The commercial launch of PRP requires further regulatory approvals in Canada, Mexico, Japan, and China, meaning Genus faces risks of regulatory delays and restricted market access.
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.
Genus Financial Performance
Revenues and expenses
Genus Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Genus stock?
Genus (GNS) has a market cap of £1.8B as of October 18, 2025.
What is the P/E ratio for Genus stock?
The price to earnings (P/E) ratio for Genus (GNS) stock is 92.56 as of October 18, 2025.
Does Genus stock pay dividends?
Yes, the Genus (GNS) stock pays dividends to shareholders. As of October 18, 2025, the dividend rate is £0.32 and the yield is 1.2%. Genus has a payout ratio of 109.33% on a trailing twelve-month basis.
When is the next Genus dividend payment date?
The next Genus (GNS) dividend payment is scheduled for December 05, 2025.
What is the beta indicator for Genus?
Genus (GNS) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.